查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1863426

CRISPR基因编辑市场按类型、应用、最终用户和交付方式划分——2025-2032年全球预测

CRISPR Gene Editing Market by Type, Application, End User, Delivery Method - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，CRISPR 基因编辑市场将成长至 136.3 亿美元，复合年增长率为 17.40%。

主要市场统计数据
基准年 2024 37.7亿美元
预计年份：2025年 44.3亿美元
预测年份：2032年 136.3亿美元
复合年增长率 (%) 17.40%

本文简要概述了当前的基因编辑生态系统、技术转折点以及影响近期策略重点的监管趋势。

基因编辑领域已从学术研究发展成为科学创新与商业性雄心交会的策略要地。 CRISPR相关核酸酶、精确碱基编辑和递送技术的最新进展，正推动其在治疗、农业和工业生物技术等领域的广泛应用，加速实用化进程。本文概述了该领域的现状，并重点介绍了影响开发者、投资者和政策制定者近期优先事项的技术转折点和监管趋势。

技术、监管和交付方面的重大突破将重塑治疗和农业基因编辑领域的策略重点和竞争优势。

过去几年发生的变革性变化正在重新定义各组织在基因编辑领域研发投资和商业化的优先顺序。精准编辑技术（例如碱基编辑和先导编辑）的进步降低了脱靶风险，并扩大了可靶向基因变化的范围，从而将治疗应用从单基因疾病扩展到复杂的多基因疾病和体细胞疾病。同时，具有不同PAM序列要求和切割机制的模组化可编程核酸酶使科学家能够针对特定基因位点量身定制编辑策略，从而提高设计效率并提升临床前模型的成功率。

美国近期关税调整对基因编辑计画的供应链、区域製造地选择和合作策略的影响

美国宣布的2025年关税调整，为依赖跨境供应链采购基因编辑计画所需试剂、设备和生物材料的机构带来了新的营运复杂性。虽然直接影响主要集中在半成品、专用设备和某些生物加工投入品上，但其连锁反应已波及采购计划、投入品替代策略和供应商多元化等各个方面。与国际供应商紧密联繫的公司面临着更长的前置作业时间和与海关合规及关税归类相关的更多行政负担。

从类型、应用程式和最终用户交付方式等方面进行观点，以确定研究重点和商业化管道的优先顺序。

了解基因编辑技术及其按应用领域分類的情况，对于协调研发重点、商业策略和投资决策至关重要。按类型划分，研究和产品系列涵盖碱基编辑、Cas9、Cpf1、先导编辑、Talen 和 Zfn，每种技术在精确度、靶点覆盖范围和操作考虑方面各有不同，这些因素会影响工具的选择和检验管道。基于应用领域，本报告涵盖农业、工业能源、研发和治疗领域。农业领域专注于作物改良和畜牧生产，反映了不同的性状靶点和监管方法。工业能源领域则强调生物基化学品和生质燃料，其中製程强化和原料优化是推动发展的关键因素。研发领域分为基础研究和药物发现，重点在于从基础科学到转化专案的整个流程。治疗领域分为体外疗法和体内疗法。体外疗法进一步包括造血干细胞疗法和 T 细胞疗法，而体内疗法则进一步包括肿瘤治疗和罕见遗传疾病治疗。每个子领域都需要不同的发行策略和临床终点。按最终用户划分，市场由学术和研究机构、农业相关企业、受託研究机构)以及製药生物技术公司组成。学术和研究机构又分为公立研究机构和大学，农业相关企业则分为动物用药品公司和农作物供应公司。 CRO 分为临床服务和非临床服务，製药生物技术公司则分为大型生物技术公司和小型生物技术公司，二者在资源基础、风险接受度和伙伴关係模式方面存在差异。技术管道按递送方式分为非病毒载体和载体载体。非病毒载体包括电穿孔、脂质奈米颗粒和物理方法，而载体载体包括质体载体和病毒载体。每种方法在生产、安全性和监管方面都有其独特的优缺点。

区域间的比较趋势和策略考量会影响全球临床试验设计、生产在地化和监管一致性。

区域趋势对基因编辑技术的发展、监管策略和商业化时间表产生了深远的影响。在美洲，生物技术丛集、创业投资和转化研究基础设施的密集分布，为从概念验证到临床试验的快速过渡提供了支持。同时，监管机构也不断更新指导意见，强调基于风险的评估和病人安全。在欧洲、中东和非洲，监管方式和公众舆论呈现出分化趋势，一些地区为基因编辑作物提供了完善的推广管道，而另一些地区则实施更为严格的监管，这就需要灵活的打入市场策略和加强相关人员之间的合作。亚太地区的特点是拥有高产能的製造地、快速扩张的临床研究网络，以及正在转向有利于某些市场治疗性和农业基因编辑的政策环境的政策框架。

策略行动和伙伴关係生态系统塑造了平台提供者、治疗方法开发商和服务机构的竞争优势。

基因编辑生态系中的公司策略正围绕着平台实力、递送能力和监理执行力趋于一致。专注于工具开发（提供核酸酶、编辑器变体和设计软体）的公司与专注于端到端治疗或农业产品开发的公司之间存在着明显的二元对立。工具提供者透过投资智慧财产权保护、开发者生态系统和开放科学合作来推动技术应用，而下游开发者则优先考虑递送解决方案、临床概念验证和生产规模化。

经营团队应优先采取的战术和组织行动，将基因编辑创新转化为稳健、符合监管要求的商业项目。

基因编辑领域的领导企业应采取一系列优先行动，将科学潜力转化为永续的商业和临床优势。首先，选择性地投资于与核心治疗和农业目标相符的递送解决方案。优先考虑已验证的非病毒载体方法用于体外实验，并确保病毒载体的供给能力，以满足持久的体内适应症需求。其次，建立监管情报能力，检验特定区域的指导意见，并能够快速调整测试设计、标籤策略和核准后证据生成。第三，实现供应链多元化，加速二级供应商和区域供应商的合格，以降低受贸易政策变化和物流中断影响的风险。

相关利益者、以证据为导向的研究，结合利害关係人访谈、科学文献综述、监管分析和基于情境的综合分析，得出策略性结论。

本研究整合了一手和二手资料，旨在全面了解基因编辑技术的技术、监管和商业性趋势。一手资料包括与跨职能相关人员进行结构化访谈和研讨会，这些利益相关者包括来自学术机构、生物技术公司、农业发展公司和服务供应商的研发负责人、生产专家、监管事务专家和商业负责人。这些访谈和研讨会旨在检验假设并探索新的最佳实践，重点关注技术成熟度、交付限制、监管策略和供应链风险缓解。

整合技术发展动能、监管演变和营运韧性，以明确基因编辑领域持续进步的策略要务。

总之，基因编辑技术正从实验性技术发展成为一个多元化的产业，技术细节、递送创新、监管清晰度和供应链韧性将决定最终结果。精准编辑模式和改进的递送技术正在拓展治疗和农业领域可行干预的可能性。不断完善的监管和公众参与正在形成一条差异化的发展路径，这条路径将奖励那些能够将技术严谨性、清晰的证据策略和透明的相关人员沟通结合的机构。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 高保真Cas9突变体的进展可减少治疗应用中的脱靶效应
  • Prime 编辑平台取得突破性进展：实现遗传疾病的多碱基校正
  • 开发用于体内组织特异性CRISPR 疗法的非病毒递送载体
  • AI驱动的CRISPR引导RNA设计工具提高了特异性并最大限度地减少了意外编辑
  • 商业化规模生产符合cGMP标准的CRISPR试剂以满足临床试验需求
  • 监管协调倡议旨在简化 CRISPR 疗法的全球核准流程
  • 将用于治疗单核苷酸疾病的碱基编辑技术整合到临床流程中。
  • 用于快速照护现场病原体检测和基因筛检的新型 CRISPR 诊断技术

第六章美国关税的累积影响，2025年

第七章 人工智慧的累积影响，2025年

8. CRISPR基因编辑市场按类型划分

  • 基础编辑
  • Cas9
  • Cpf1
  • Prime Edit
  • 塔伦
  • Zfn

9. CRISPR基因编辑市场按应用领域划分

  • 农业
    • 作物改良
    • 家畜
  • 工业能源
    • 生物基化学品
    • 生质燃料
  • 研究与开发
    • 基础研究
    • 药物发现
  • 治疗
    • 体外治疗
      • 造血干细胞疗法
      • T细胞疗法
    • 内科治疗
      • 肿瘤学
      • 罕见遗传疾病

第十章 CRISPR基因编辑市场（按最终用户划分）

  • 学术和研究机构
    • 公共研究机构
    • 大学
  • 农业相关企业
    • 动物用药品公司
    • 农作物供应商
  • 受託研究机构
    • 临床服务
    • 临床前服务
  • 製药和生物技术公司
    • 大型製药企业
    • 中小型生技公司

11. CRISPR基因编辑市场以交付方式划分

  • 非病毒方法
    • 电穿孔
    • 脂质奈米颗粒
    • 物理方法
  • 向量
    • 质体载体
    • 病毒载体

12. CRISPR基因编辑市场（按地区划分）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章 CRISPR基因编辑市场（依群体划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 各国 CRISPR 基因编辑市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Thermo Fisher Scientific Inc.
    • Merck KGaA
    • Danaher Corporation
    • Agilent Technologies, Inc.
    • Qiagen NV
    • New England Biolabs, Inc.
    • Illumina, Inc.
    • GenScript BIoTech Corporation
    • Synthego, Inc.
    • Takara Bio Inc.
Product Code: MRR-5C6F41F5AF91

The CRISPR Gene Editing Market is projected to grow by USD 13.63 billion at a CAGR of 17.40% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 3.77 billion
Estimated Year [2025] USD 4.43 billion
Forecast Year [2032] USD 13.63 billion
CAGR (%) 17.40%

A concise orientation to the current gene editing ecosystem, technological inflection points, and evolving regulatory dynamics shaping near-term strategic priorities

The gene editing landscape has evolved from academic curiosity into a strategic arena where scientific innovation and commercial ambition intersect. Recent advances in CRISPR-associated nucleases, precision base editing, and delivery technologies have accelerated translational pathways, enabling a broad set of applications across therapeutics, agriculture, and industrial biotechnology. This introduction frames the current state of the field, highlighting the technological inflection points and regulatory developments that are shaping near-term priorities for developers, investors, and policy makers.

Technological progress has been accompanied by a maturing ecosystem of service providers, platform companies, and collaborative consortia that de-risk early-stage development and enable scale-up. Simultaneously, regulatory bodies in multiple jurisdictions are refining guidance for gene-edited products, which is creating clearer pathways while also introducing novel compliance obligations. Together, these dynamics are redefining competitive advantage: leaders will be those that pair rigorous science with pragmatic regulatory strategy, robust delivery solutions, and evidence-driven clinical or field validation. This introduction sets the stage for a deeper analysis of transformative shifts, tariff impacts, segmentation insights, regional dynamics, and actionable recommendations for organizations operating in this rapidly changing domain.

Critical technological, regulatory, and delivery breakthroughs reshaping strategic priorities and competitive advantage across therapeutic and agricultural gene editing

The past several years have produced transformative shifts that are redefining how organizations prioritize R&D investment and commercialization in gene editing. Advances in precision modalities such as base editing and prime editing are reducing off-target risk and expanding the set of addressable genetic alterations, which in turn is broadening therapeutic applications beyond single-gene disorders into complex polygenic and somatic indications. Meanwhile, modular programmable nucleases with differing PAM requirements and cleavage mechanics are allowing scientists to tailor editing strategies to specific loci, driving more efficient design cycles and higher success rates in preclinical models.

Concurrently, delivery science has moved from an unresolved bottleneck to a competitive differentiator. Improvements in lipid nanoparticle formulations, electroporation methods, and hybrid non-viral systems are enabling safer and more efficient ex vivo and in vivo interventions. These advances are complemented by increased investment in scalable vector production and manufacturing process intensification, which are critical to translate laboratory successes into clinically and commercially viable products.

Policy and public perception have also shifted. Regulatory agencies are publishing clearer guidance and adopting science-based frameworks; however, the global regulatory topology remains heterogeneous. This unevenness is encouraging parallel development strategies and regionally optimized trial designs. As a result, strategic alliances, cross-sector partnerships, and platform licensing arrangements are becoming a dominant business model to accelerate time-to-evidence and broaden access to capabilities. Together, these shifts suggest a landscape in which speed to reliable clinical or agricultural proof, secure supply chains, and regulatory agility will determine competitive outcomes.

How recent U.S. tariff revisions are reshaping supply chains, regional manufacturing choices, and collaborative research strategies for gene editing programs

Tariff adjustments announced in 2025 by the United States have introduced a new layer of operational complexity for organizations that rely on cross-border supply chains for reagents, equipment, and biological materials integral to gene editing programs. While the immediate impact has been concentrated on intermediate goods, specialized instruments, and certain bioprocess inputs, the reverberations extend to procurement timelines, input substitution strategies, and supplier diversification efforts. Companies with tightly coupled international suppliers have experienced elongation of lead times and an increased administrative burden associated with customs compliance and tariff classification.

In response, many organizations have accelerated regionalization strategies, expanding local sourcing and qualifying multiple vendors across jurisdictions to mitigate exposure. This has led to a reprioritization of capital spend toward local manufacturing capacity, inventory buffers, and onshore production of high-value components. Moreover, tariff-driven cost pressures have elevated the importance of operational excellence initiatives that reduce waste and improve reagent utilization, thereby lowering dependency on high-cost imported materials.

The policy shift has also impacted collaborative research models. Cross-border specimen exchange and collaborative reagent sharing now require more detailed contractual frameworks to address potential cost reallocations and regulatory compliance. Clinical and field trial sponsors are reassessing site selection criteria to account for supply resilience and total program risk. Taken together, the tariff changes have catalyzed strategic realignment across sourcing, manufacturing, and partnership structures, incentivizing greater domestic capacity and more robust supplier governance to preserve program timelines and control costs without diluting scientific rigor.

Integrated segmentation perspectives that connect types, applications, end users, and delivery methods to prioritize research focus and commercialization pathways

Understanding the segmentation of gene editing technologies and applications is essential to aligning R&D priorities, commercial strategies, and investment decisions. Based on Type, research and product portfolios span Base Editing, Cas9, Cpf1, Prime Editing, Talen, and Zfn, each offering distinct precision, target range, and operational considerations that influence tool selection and validation pathways. Based on Application, the field covers Agriculture, Industrial & Energy, Research & Development, and Therapeutic; within Agriculture there is a focus on Crop Improvement and Livestock, reflecting different trait targets and regulatory approaches, while Industrial & Energy applications emphasize Bio-based Chemicals and Biofuels with process intensification and feedstock optimization driving development. The Research & Development segment is differentiated into Basic Research and Drug Discovery, underscoring the pipeline from foundational science to translational programs, and the Therapeutic segment separates Ex Vivo Therapy and In Vivo Therapy, where Ex Vivo Therapy further includes Hematopoietic Stem Cell Therapy and T Cell Therapy and In Vivo Therapy further includes Oncology and Rare Genetic Disorders, each subsegment demanding distinct delivery strategies and clinical endpoints. Based on End User, the ecosystem comprises Academic & Research Institutes, Agricultural Companies, Contract Research Organizations, and Pharma & Biotech Companies, with the Academic & Research Institutes category differentiated into Public Research Institutes and Universities, Agricultural Companies split into Animal Health Companies and Crop Providers, Contract Research Organizations divided into Clinical Services and Preclinical Services, and Pharma & Biotech Companies segmented into Large Pharma and Small & Medium Biotech, which together reflect different resource bases, risk appetites, and partnership models. Based on Delivery Method, technological pathways are categorized into Non-Viral Methods and Vectors; Non-Viral Methods include Electroporation, Lipid Nanoparticles, and Physical Methods while Vectors encompass Plasmid Vectors and Viral Vectors, each with unique manufacturing, safety, and regulatory trade-offs.

Applying these segmentation lenses reveals where scientific innovation intersects with commercial feasibility. For example, precision modalities such as base editing and prime editing are finding rapid adoption in basic research and drug discovery because they reduce the need for complex vector engineering, while viral vectors remain central to many in vivo therapeutic programs that require durable expression. Agricultural applications are bifurcated between crop trait engineering, which can leverage tissue culture and gene drive-adjacent strategies, and livestock applications that prioritize welfare, breeding timelines, and regulatory clarity. End users differ dramatically in procurement cadence and validation expectations: academic centers often prioritize flexibility and open-source tools, whereas large pharmaceutical firms demand validated supply chains, GMP-compliant materials, and comprehensive regulatory dossiers. Finally, delivery method choices are often determined by a program's target cells and required duration of effect, with non-viral approaches increasingly competitive in ex vivo workflows and some in vivo niches due to safety and manufacturing scalability.

Comparative regional dynamics and strategic considerations that influence trial design, manufacturing localization, and regulatory alignment across global jurisdictions

Regional dynamics are exerting a powerful influence on technology development, regulatory strategy, and commercialization timelines in gene editing. In the Americas, a dense concentration of biotechnology clusters, venture capital, and translational research infrastructure supports rapid movement from proof-of-concept to clinical trial initiation, while regulatory agencies are publishing evolving guidance that emphasizes risk-based evaluation and patient safety. Europe, Middle East & Africa presents a mosaic of regulatory approaches and public sentiment, with some jurisdictions offering progressive pathways for gene-edited crops and others applying stricter oversight, necessitating flexible go-to-market strategies and enhanced stakeholder engagement. Asia-Pacific is characterized by a mix of high-capacity manufacturing hubs, rapidly expanding clinical research networks, and policy environments that, in select markets, are moving toward enabling frameworks for both therapeutic and agricultural gene editing.

These regional contrasts are shaping where companies invest in trials, manufacturing capacity, and partnerships. For instance, clinical programs targeting rare genetic disorders may prioritize regions with streamlined orphan drug pathways and access to specialized clinical sites, while agricultural trait developers often select jurisdictions with clearer product differentiation between gene editing and transgenesis. Supply chain resilience considerations are also regional: localized reagent production and contract manufacturing capabilities can mitigate the impact of trade policy shifts and logistics disruptions. Strategic investors and corporate leaders must therefore adopt a regionally nuanced approach that balances speed to evidence, regulatory predictability, manufacturing access, and stakeholder acceptance across the Americas, Europe, Middle East & Africa, and Asia-Pacific to optimize program outcomes.

Strategic behaviors and partnership ecosystems shaping competitive advantage for platform providers, therapeutic developers, and service organizations

Company strategies within the gene editing ecosystem are coalescing around platform strength, delivery capabilities, and regulatory execution. There is a clear bifurcation between organizations that focus on tool development-providing nucleases, editor variants, and design software-and those that concentrate on end-to-end therapeutic or agricultural product development. Tool providers are investing in intellectual property protection, developer ecosystems, and open-science collaborations to drive widespread adoption, while downstream developers are prioritizing delivery solutions, clinical proof-of-concept, and manufacturing scale-up.

Partnership models are increasingly sophisticated: strategic alliances, licensing deals, and co-development agreements enable companies to combine complementary strengths such as vector manufacturing, clinical operations, and regulatory affairs. Service providers and contract research organizations are expanding capabilities to include GMP-grade reagent supply, scalable process development, and regulatory consulting, which reduces time and risk for smaller developers. Investment activity remains robust in platform technologies and delivery innovations, and leadership in commercial outcomes will likely belong to organizations that can integrate high-fidelity editing modalities with validated delivery systems, robust manufacturing processes, and a demonstrated regulatory pathway. Executives should also monitor emerging entrants specializing in niche enabling technologies-such as improved nuclease variants, novel nanoparticle chemistries, and automated cell engineering platforms-that can offer asymmetric advantages to larger integrated players through licensing or acquisition.

Priority tactical and organizational actions executives should implement to convert gene editing innovations into resilient, regulation-ready commercial programs

Leaders in gene editing should adopt a set of prioritized actions that translate scientific promise into durable commercial and clinical advantage. First, invest selectively in delivery solutions that align with core therapeutic or agricultural targets; prioritizing validated non-viral approaches for ex vivo programs and ensuring viral vector capacity for in vivo indications where durability is required. Second, build regulatory intelligence capabilities that track region-specific guidance and enable rapid adaptation of trial design, labeling strategy, and post-approval evidence generation. Third, diversify supply chains and accelerate qualification of secondary vendors and regional suppliers to reduce exposure to trade policy shifts and logistics disruptions.

Beyond operational resilience, organizations should cultivate strategic partnerships that map complementary strengths-combining platform providers' molecular innovation with developers' clinical infrastructure and commercialization experience. Consider flexible commercial models such as staged licensing and milestone-based co-development to share risk and align incentives. Additionally, invest in talent that bridges molecular biology, process engineering, and regulatory science to accelerate translational readiness. Finally, maintain proactive stakeholder engagement programs that communicate safety profiles, benefit-risk trade-offs, and societal value propositions to patients, farmers, regulators, and the public; this will be essential to sustaining social license and mitigating reputational risk as applications expand into new domains.

A transparent and evidence-driven research approach combining stakeholder interviews, scientific literature review, regulatory analysis, and scenario-based synthesis to inform strategic conclusions

This research synthesized primary and secondary inputs to develop a holistic view of technological, regulatory, and commercial dynamics in gene editing. Primary research included structured interviews and workshop sessions with cross-functional stakeholders such as R&D leads, manufacturing experts, regulatory affairs professionals, and commercial strategists drawn from academic institutions, biotechnology companies, agricultural developers, and service providers. These engagements focused on technology readiness, delivery constraints, regulatory strategy, and supply chain risk mitigation, and they were used to validate hypotheses and surface emerging best practices.

Secondary research encompassed peer-reviewed scientific literature, policy statements from regulatory agencies, clinical trial registries, patent filings, company technical disclosures, and industry conference proceedings. Data synthesis prioritized triangulation across sources to ensure robustness and to identify convergent trends versus outlier signals. Scenario analysis was applied to evaluate the implications of regulatory divergence, tariff changes, and delivery technology adoption on program execution. The methodology emphasizes transparency in assumptions and a defensible linkage between technical evidence and strategic implications, enabling decision-makers to adapt recommendations to specific organizational contexts.

Synthesis of technological momentum, regulatory evolution, and operational resilience that defines the strategic imperative for sustained progress in gene editing

In conclusion, gene editing is transitioning from experimental methods to a multifaceted industry where technical nuance, delivery innovation, regulatory clarity, and supply chain resilience determine outcomes. Precision editing modalities and improved delivery technologies are expanding the horizon of feasible interventions across both therapeutic and agricultural domains. Regulatory evolution and public engagement are creating differentiated pathways that will reward organizations capable of aligning technical rigor with clear evidence strategies and transparent stakeholder communication.

Operationally, the combination of tariff-driven supply chain pressures and regional variation in regulatory approaches underscores the necessity of diversified sourcing, regional manufacturing capacity, and agile clinical or field deployment plans. Strategic collaboration remains a cornerstone of progress: platform developers, service providers, and end-product developers must continue to form alliances that accelerate validation and de-risk scale-up. Organizations that invest in delivery platforms, regulatory intelligence, and resilient supply models will be best positioned to translate gene editing capabilities into enduring clinical and commercial impact. The path forward requires an integrated approach that balances scientific excellence with pragmatic execution.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Advancements in high-fidelity Cas9 variants reducing off-target effects in therapeutic applications
  • 5.2. Breakthroughs in prime editing platforms enabling multi-base corrections for genetic diseases
  • 5.3. Development of nonviral delivery vectors for tissue-specific CRISPR therapeutics in vivo
  • 5.4. AI-driven CRISPR guide RNA design tools enhancing specificity and minimizing unintended edits
  • 5.5. Commercial scaling of cGMP manufacturing for CRISPR reagents to support clinical trial demand
  • 5.6. Regulatory alignment initiatives streamlining global approval processes for CRISPR therapies
  • 5.7. Integration of base editing technologies targeting single-nucleotide disorders in clinical pipelines
  • 5.8. Emerging CRISPR diagnostics for rapid point-of-care pathogen detection and genetic screening

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. CRISPR Gene Editing Market, by Type

  • 8.1. Base Editing
  • 8.2. Cas9
  • 8.3. Cpf1
  • 8.4. Prime Editing
  • 8.5. Talen
  • 8.6. Zfn

9. CRISPR Gene Editing Market, by Application

  • 9.1. Agriculture
    • 9.1.1. Crop Improvement
    • 9.1.2. Livestock
  • 9.2. Industrial & Energy
    • 9.2.1. Bio-based Chemicals
    • 9.2.2. Biofuels
  • 9.3. Research & Development
    • 9.3.1. Basic Research
    • 9.3.2. Drug Discovery
  • 9.4. Therapeutic
    • 9.4.1. Ex Vivo Therapy
      • 9.4.1.1. Hematopoietic Stem Cell Therapy
      • 9.4.1.2. T Cell Therapy
    • 9.4.2. In Vivo Therapy
      • 9.4.2.1. Oncology
      • 9.4.2.2. Rare Genetic Disorders

10. CRISPR Gene Editing Market, by End User

  • 10.1. Academic & Research Institutes
    • 10.1.1. Public Research Institutes
    • 10.1.2. Universities
  • 10.2. Agricultural Companies
    • 10.2.1. Animal Health Companies
    • 10.2.2. Crop Providers
  • 10.3. Contract Research Organizations
    • 10.3.1. Clinical Services
    • 10.3.2. Preclinical Services
  • 10.4. Pharma & Biotech Companies
    • 10.4.1. Large Pharma
    • 10.4.2. Small & Medium Biotech

11. CRISPR Gene Editing Market, by Delivery Method

  • 11.1. Non-Viral Methods
    • 11.1.1. Electroporation
    • 11.1.2. Lipid Nanoparticles
    • 11.1.3. Physical Methods
  • 11.2. Vectors
    • 11.2.1. Plasmid Vectors
    • 11.2.2. Viral Vectors

12. CRISPR Gene Editing Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. CRISPR Gene Editing Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. CRISPR Gene Editing Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Thermo Fisher Scientific Inc.
    • 15.3.2. Merck KGaA
    • 15.3.3. Danaher Corporation
    • 15.3.4. Agilent Technologies, Inc.
    • 15.3.5. Qiagen N.V.
    • 15.3.6. New England Biolabs, Inc.
    • 15.3.7. Illumina, Inc.
    • 15.3.8. GenScript Biotech Corporation
    • 15.3.9. Synthego, Inc.
    • 15.3.10. Takara Bio Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CRISPR GENE EDITING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY DELIVERY METHOD, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY DELIVERY METHOD, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS CRISPR GENE EDITING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA CRISPR GENE EDITING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA CRISPR GENE EDITING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA CRISPR GENE EDITING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE CRISPR GENE EDITING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST CRISPR GENE EDITING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA CRISPR GENE EDITING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC CRISPR GENE EDITING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN CRISPR GENE EDITING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC CRISPR GENE EDITING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION CRISPR GENE EDITING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS CRISPR GENE EDITING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 CRISPR GENE EDITING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO CRISPR GENE EDITING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. CRISPR GENE EDITING MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. CRISPR GENE EDITING MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. CRISPR GENE EDITING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL CRISPR GENE EDITING MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL CRISPR GENE EDITING MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY BASE EDITING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY BASE EDITING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY BASE EDITING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY BASE EDITING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY BASE EDITING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY BASE EDITING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY CAS9, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY CAS9, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY CAS9, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY CAS9, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY CAS9, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY CAS9, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY CPF1, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY CPF1, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY CPF1, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY CPF1, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY CPF1, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY CPF1, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY PRIME EDITING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY PRIME EDITING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY PRIME EDITING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY PRIME EDITING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY PRIME EDITING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY PRIME EDITING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY TALEN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY TALEN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY TALEN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY TALEN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY TALEN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY TALEN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY ZFN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY ZFN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY ZFN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY ZFN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY ZFN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY ZFN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY AGRICULTURE, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY AGRICULTURE, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY AGRICULTURE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY AGRICULTURE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY AGRICULTURE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY AGRICULTURE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY AGRICULTURE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY AGRICULTURE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY CROP IMPROVEMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY CROP IMPROVEMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY CROP IMPROVEMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY CROP IMPROVEMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY CROP IMPROVEMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY CROP IMPROVEMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY LIVESTOCK, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY LIVESTOCK, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY LIVESTOCK, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY LIVESTOCK, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY LIVESTOCK, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY LIVESTOCK, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY INDUSTRIAL & ENERGY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY INDUSTRIAL & ENERGY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY INDUSTRIAL & ENERGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY INDUSTRIAL & ENERGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY INDUSTRIAL & ENERGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY INDUSTRIAL & ENERGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY INDUSTRIAL & ENERGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY INDUSTRIAL & ENERGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY BIO-BASED CHEMICALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY BIO-BASED CHEMICALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY BIO-BASED CHEMICALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY BIO-BASED CHEMICALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY BIO-BASED CHEMICALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY BIO-BASED CHEMICALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY BIOFUELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY BIOFUELS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY BIOFUELS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY BIOFUELS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY BIOFUELS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY BIOFUELS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY RESEARCH & DEVELOPMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY RESEARCH & DEVELOPMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY RESEARCH & DEVELOPMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY RESEARCH & DEVELOPMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY RESEARCH & DEVELOPMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY RESEARCH & DEVELOPMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY BASIC RESEARCH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY BASIC RESEARCH, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY BASIC RESEARCH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY BASIC RESEARCH, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY BASIC RESEARCH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY BASIC RESEARCH, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY DRUG DISCOVERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY DRUG DISCOVERY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY DRUG DISCOVERY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY DRUG DISCOVERY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY DRUG DISCOVERY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY DRUG DISCOVERY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY THERAPEUTIC, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY THERAPEUTIC, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY THERAPEUTIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY THERAPEUTIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY THERAPEUTIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY THERAPEUTIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY THERAPEUTIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY THERAPEUTIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY EX VIVO THERAPY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY EX VIVO THERAPY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY EX VIVO THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY EX VIVO THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY EX VIVO THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY EX VIVO THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY EX VIVO THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY EX VIVO THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY HEMATOPOIETIC STEM CELL THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY HEMATOPOIETIC STEM CELL THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY HEMATOPOIETIC STEM CELL THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY HEMATOPOIETIC STEM CELL THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY HEMATOPOIETIC STEM CELL THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY HEMATOPOIETIC STEM CELL THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY T CELL THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY T CELL THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY T CELL THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY T CELL THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY T CELL THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY T CELL THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY IN VIVO THERAPY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY IN VIVO THERAPY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY IN VIVO THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY IN VIVO THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY IN VIVO THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY IN VIVO THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY IN VIVO THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY IN VIVO THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY ONCOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY RARE GENETIC DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY RARE GENETIC DISORDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY RARE GENETIC DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY RARE GENETIC DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY RARE GENETIC DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY RARE GENETIC DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY PUBLIC RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY PUBLIC RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY PUBLIC RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY PUBLIC RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY PUBLIC RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY PUBLIC RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY UNIVERSITIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY UNIVERSITIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY UNIVERSITIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY UNIVERSITIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY UNIVERSITIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY UNIVERSITIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY AGRICULTURAL COMPANIES, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY AGRICULTURAL COMPANIES, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY AGRICULTURAL COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY AGRICULTURAL COMPANIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY AGRICULTURAL COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY AGRICULTURAL COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY AGRICULTURAL COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY AGRICULTURAL COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY ANIMAL HEALTH COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY ANIMAL HEALTH COMPANIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY ANIMAL HEALTH COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY ANIMAL HEALTH COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY ANIMAL HEALTH COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY ANIMAL HEALTH COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY CROP PROVIDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY CROP PROVIDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY CROP PROVIDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY CROP PROVIDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY CROP PROVIDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY CROP PROVIDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY CLINICAL SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY CLINICAL SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY CLINICAL SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY CLINICAL SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY CLINICAL SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY CLINICAL SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY PRECLINICAL SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY PRECLINICAL SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY PRECLINICAL SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY PRECLINICAL SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY PRECLINICAL SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY PRECLINICAL SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY PHARMA & BIOTECH COMPANIES, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY PHARMA & BIOTECH COMPANIES, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY PHARMA & BIOTECH COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY PHARMA & BIOTECH COMPANIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY PHARMA & BIOTECH COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY PHARMA & BIOTECH COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY PHARMA & BIOTECH COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY PHARMA & BIOTECH COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY LARGE PHARMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY LARGE PHARMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY LARGE PHARMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY LARGE PHARMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY LARGE PHARMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY LARGE PHARMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY SMALL & MEDIUM BIOTECH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY SMALL & MEDIUM BIOTECH, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY SMALL & MEDIUM BIOTECH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY SMALL & MEDIUM BIOTECH, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY SMALL & MEDIUM BIOTECH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY SMALL & MEDIUM BIOTECH, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY DELIVERY METHOD, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY NON-VIRAL METHODS, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY NON-VIRAL METHODS, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY NON-VIRAL METHODS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY NON-VIRAL METHODS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY NON-VIRAL METHODS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY NON-VIRAL METHODS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY NON-VIRAL METHODS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY NON-VIRAL METHODS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY ELECTROPORATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY ELECTROPORATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY ELECTROPORATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY ELECTROPORATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY ELECTROPORATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY ELECTROPORATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY LIPID NANOPARTICLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY LIPID NANOPARTICLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY LIPID NANOPARTICLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY LIPID NANOPARTICLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY LIPID NANOPARTICLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY LIPID NANOPARTICLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY PHYSICAL METHODS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY PHYSICAL METHODS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY PHYSICAL METHODS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY PHYSICAL METHODS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY PHYSICAL METHODS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY PHYSICAL METHODS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY VECTORS, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY VECTORS, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY VECTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY VECTORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY VECTORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY VECTORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY VECTORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY VECTORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY PLASMID VECTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY PLASMID VECTORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 273. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY PLASMID VECTORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 274. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY PLASMID VECTORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY PLASMID VECTORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY PLASMID VECTORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 277. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY VIRAL VECTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 278. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY VIRAL VECTORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 279. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY VIRAL VECTORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 280. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY VIRAL VECTORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 281. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY VIRAL VECTORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 282. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY VIRAL VECTORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 283. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 284. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 285. AMERICAS CRISPR GENE EDITING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 286. AMERICAS CRISPR GENE EDITING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 287. AMERICAS CRISPR GENE EDITING MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 288. AMERICAS CRISPR GENE EDITING MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 289. AMERICAS CRISPR GENE EDITING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 290. AMERICAS CRISPR GENE EDITING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 291. AMERICAS CRISPR GENE EDITING MARKET SIZE, BY AGRICULTURE, 2018-2024 (USD MILLION)
  • TABLE 292. AMERICAS CRISPR GENE EDITING MARKET SIZE, BY AGRICULTURE, 2025-2032 (USD MILLION)
  • TABLE 293. AMERICAS CRISPR GENE EDITING MARKET SIZE, BY INDUSTRIAL & ENERGY, 2018-2024 (USD MILLION)
  • TABLE 294. AMERICAS CRISPR GENE EDITING MARKET SIZE, BY INDUSTRIAL & ENERGY, 2025-2032 (USD MILLION)
  • TABLE 295. AMERICAS CRISPR GENE EDITING MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2024 (USD MILLION)
  • TABLE 296. AMERICAS CRISPR GENE EDITING MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2025-2032 (USD MILLION)
  • TABLE 297. AMERICAS CRISPR GENE EDITING MARKET SIZE, BY THERAPEUTIC, 2018-2024 (USD MILLION)
  • TABLE 298. AMERICAS CRISPR GENE EDITING MARKET SIZE, BY THERAPEUTIC, 2025-2032 (USD MILLION)
  • TABLE 299. AMERICAS CRISPR GENE EDITING MARKET SIZE, BY EX VIVO THERAPY, 2018-2024 (USD MILLION)
  • TABLE 300. AMERICAS CRISPR GENE EDITING MARKET SIZE, BY EX VIVO THERAPY, 2025-2032 (USD MILLION)
  • TABLE 301. AMERICAS CRISPR GENE EDITING MARKET SIZE, BY IN VIVO THERAPY, 2018-2024 (USD MILLION)
  • TABLE 302. AMERICAS CRISPR GENE EDITING MARKET SIZE, BY IN VIVO THERAPY, 2025-2032 (USD MILLION)
  • TABLE 303. AMERICAS CRISPR GENE EDITING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 304. AMERICAS CRISPR GENE EDITING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 305. AMERICAS CRISPR GENE EDITING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2024 (USD MILLION)
  • TABLE 306. AMERICAS CRISPR GENE EDITING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2025-2032 (USD MILLION)
  • TABLE 307. AMERICAS CRISPR GENE EDITING MARKET SIZE, BY AGRICULTURAL COMPANIES, 2018-2024 (USD MILLION)
  • TABLE 308. AMERICAS CRISPR GENE EDITING MARKET SIZE, BY AGRICULTURAL COMPANIES, 2025-2032 (USD MILLION)
  • TABLE 309. AMERICAS CRISPR GENE EDITING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2024 (USD MILLION)
  • TABLE 310. AMERICAS CRISPR GENE EDITING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2025-2032 (USD MILLION)
  • TABLE 311. AMERICAS CRISPR GENE EDITING MARKET SIZE, BY PHARMA & BIOTECH COMPANIES, 2018-2024 (USD MILLION)
  • TABLE 312. AMERICAS CRISPR GENE EDITING MARKET SIZE, BY PHARMA & BIOTECH COMPANIES, 2025-2032 (USD MILLION)
  • TABLE 313. AMERICAS CRISPR GENE EDITING MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
  • TABLE 314. AMERICAS CRISPR GENE EDITING MARKET SIZE, BY DELIVERY METHOD, 2025-2032 (USD MILLION)
  • TABLE 315. AMERICAS CRISPR GENE EDITING MARKET SIZE, BY NON-VIRAL METHODS, 2018-2024 (USD MILLION)
  • TABLE 316. AMERICAS CRISP